GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
These four S&P 500 stocks pay 6% and higher dividends, have Buy ratings at top Wall Street firms, and are offering excellent ...
The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...
NEW YORK CITY, New York: At the start of 2025, drug companies raised prices on over 250 brand-name medications in the U.S., ...
The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.
The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.
The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...
More than 250 medications, including Paxlovid and cancer therapies, will see price increases in the United States beginning ...
Pharmaceutical companies are raising the price of over 250 brand drugs this year. Nearly all the price increases are under 10 ...
Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback